Platelet‑rich plasma (PRP) has become one of the most widely used regenerative therapies in orthopedic and aesthetic medicine. As clinicians and patients seek non‑pharmacologic, minimally invasive options for joint pain and hair loss, PRP offers a biologically plausible and increasingly well‑studied intervention. Yet, its use remains heterogeneous, and regulatory oversight is often misunderstood. This review summarizes the current evidence, FDA considerations, benefits, risks